Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
Crossref DOI link: https://doi.org/10.1186/s12913-019-4829-z
Published Online: 2019-12-18
Published Print: 2019-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mansell, Kerry
Bhimji, Hishaam
Eurich, Dean
Mansell, Holly
Text and Data Mining valid from 2019-12-01
Version of Record valid from 2019-12-18
Article History
First Online: 18 December 2019